scholarly journals Dynamics of the Antibody Response After a Third Dose of Measles-Mumps-Rubella Vaccine Indicate a Slower Decline Compared With a Second Dose

2020 ◽  
Vol 7 (11) ◽  
Author(s):  
Patricia Kaaijk ◽  
M Alina Nicolaie ◽  
Debbie van Rooijen ◽  
Marianne A van Houten ◽  
Fiona R van der Klis ◽  
...  
Keyword(s):  
Young Adults ◽  
Antibody Response ◽  
Decay Rates ◽  
Igg Antibody ◽  
Rubella Vaccine ◽  
Blood Samples ◽  
Children And Young Adults ◽  
Antibody Levels ◽  
Induced Immunity

Abstract Background Breakthrough infections of measles and mumps have raised concerns about the duration of vaccine-induced immunity, which might be improved by a third dose of measles-mumps-rubella vaccine (MMR3). Methods Here we compared (IgG) antibody levels against measles, mumps, and rubella in blood samples of 9-year-old children and young adults (18–25 years) following MMR2 and MMR3, respectively. Results We found that, in addition to antibody boosting for all 3 vaccine components, MMR3 resulted in lower antibody decay rates than MMR2; the declines were most prominent for mumps and rubella. Conclusions This study suggests that MMR3 provides long-lasting seroprotection against measles, mumps, and rubella.

scholarly journals Longitudinal analysis of antibody decay in convalescent COVID-19 patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Weiming Xia ◽  
Mingfei Li ◽  
Ying Wang ◽  
Lewis E. Kazis ◽  
Kim Berlo ◽  
...  
Keyword(s):  
Immune Response ◽  
Reduction Rate ◽  
Mixed Linear Model ◽  
Decay Rates ◽  
Primary Study ◽  
Igg Antibody ◽  
Blood Samples ◽  
Response Capacity ◽  
Index Level ◽  
Abbott Architect

AbstractDetermining the sustainability of antibodies targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for predicting immune response against the Coronavirus disease 2019 (COVID-19). To quantify the antibody decay rates among the varying levels of anti-nucleocapsid (anti-N) Immunoglobulin G (IgG) in convalescent COVID-19 patients and estimate the length of time they maintained SARS-CoV-2 specific antibodies, we have collected longitudinal blood samples from 943 patients over the course of seven months after their initial detection of SARS-CoV-2 virus by RT-PCR. Anti-N IgG levels were then quantified in these blood samples. The primary study outcome was the comparison of antibody decay rates from convalescent patients with high or low initial levels of antibodies using a mixed linear model. Additional measures include the length of time that patients maintain sustainable levels of anti-N IgG. Antibody quantification of blood samples donated by the same subject multiple times shows a gradual decrease of IgG levels to the cutoff index level of 1.4 signal/cut-off (S/C) on the Abbott Architect SARS-CoV-2 IgG test. In addition, this study shows that antibody reduction rate is dependent on initial IgG levels, and patients with initial IgG levels above 3 S/C show a significant 1.68-fold faster reduction rate compared to those with initial IgG levels below 3 S/C. For a majority of the donors naturally occurring anti-N antibodies were detected above the threshold for only four months after infection with SARS-CoV-2. This study is clinically important for the prediction of immune response capacity in COVID-19 patients.

scholarly journals Distinct age-specific SARS-CoV-2 IgG decay kinetics following natural infection

2021 ◽  
Author(s):  
Calvin P Sjaarda ◽  
Emily Moslinger ◽  
Kyla Tozer ◽  
Robert I Colautti ◽  
Samira Kheitan ◽  
...  
Keyword(s):  
Natural Infection ◽  
Decay Rates ◽  
Decay Kinetics ◽  
Serum Samples ◽  
Igg Antibody ◽  
Multi Centre Study ◽  
Viral Neutralization ◽  
Antibody Levels ◽  
Over Time

Background. Antibody responses to SARS-CoV-2 can be observed as early as 14 days post- infection, but little is known about the stability of antibody levels over time. Here we evaluate the long-term stability of anti-SARS-CoV-2 IgG antibodies following infection in 402 adult donors. Methods. We performed a multi-centre study carried out at Plasma Donor Centres in the city of Heidelberg (Plasmazentrum Heidelberg, Germany) and Munich (Plasmazentrum M&uumlnchen, Germany). We present anti-S/N and anti-N IgG antibody levels in prospective serum samples collected up to 403 days post recovery from SARS-CoV-2 infected individuals. Results: The cohort includes 402 adult donors (185 female, 217 male; 17 - 68 years of age) where anti-SARS-CoV-2 IgG levels were measured in plasma samples collected between 18- and 403-days post SARS-CoV-2 infection. A linear mixed effects model demonstrated IgG decay rates that decrease over time (χ2=176.8, p<0.00001) and an interaction of time*age (χ2=10.0, p<0.005)), with those over 60+ years showing the highest baseline IgG levels and the fastest rate of IgG decay. Baseline viral neutralization assays demonstrated that serum IgG levels correlated with in vitro neutralization capacity in 91% of our cohort. Conclusion. Long-term antibody levels and age-specific antibody decay rates suggest the potential need for age-specific vaccine booster guidelines to ensure long term vaccine protection against SARS-CoV-2 infection.

scholarly journals Multiple Antigenic Peptide-Based Vaccines Targeting Ixodes ricinus Neuropeptides Induce a Specific Antibody Response but Do Not Impact Tick Infestation

Pathogens ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 900
Author(s):  
Consuelo Almazán ◽  
Ladislav Šimo ◽  
Lisa Fourniol ◽  
Sabine Rakotobe ◽  
Jérémie Borneres ◽  
...  
Keyword(s):  
Antibody Response ◽  
Ixodes Ricinus ◽  
Antigenic Peptide ◽  
Tick Feeding ◽  
Igg Antibody ◽  
Individual Level ◽  
Multiple Antigenic Peptide ◽  
New Strategy ◽  
The Individual ◽  
Antibody Levels

Synthetic peptide vaccines were designed to target the neuropeptides innervating Ixodes ricinus salivary glands and hindgut and they were tested for their capacity to afford protective immunity against nymphs or larvae and Anaplasma phagocytophilum-infected nymph infestation, in mice and sheep, respectively. In both models, the assembly of SIFamide (SIFa) or myoinhibitory peptide (MIP) neuropeptides into multiple antigenic peptide constructs (MAPs) elicited a robust IgG antibody response following immunization. Nevertheless, no observable detrimental impact on nymphs was evidenced in mice, and, unfortunately, the number of engorged nymphs on sheep was insufficient for firm conclusions to be drawn, including for bacterial transmission. Regarding larvae, while vaccination of the sheep did not globally diminish tick feeding success or development, analyses of animals at the individual level revealed a negative correlation between anti-SIFa and MIP antibody levels and larva-to-nymph molting success for both antigens. Our results provide a proof of principle and precedent for the use of MAPs for the induction of immunity against tick peptide molecules. Although the present study did not provide the expected level of protection, it inaugurates a new strategy for protection against ticks based on the immunological targeting of key components of their nervous system.

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Infants

1980 ◽  
Vol 89 (3_suppl) ◽  
pp. 351-356 ◽  
Author(s):  
John L. Sloyer ◽  
Laurel J. Karr ◽  
John H. Ploussard ◽  
Gerald D. Schiffman
Keyword(s):  
Antibody Response ◽  
Otitis Media ◽  
Natural Infection ◽  
Young Infant ◽  
Serum Antibody ◽  
Capsular Polysaccharides ◽  
Igg Antibody ◽  
Nasopharyngeal Colonization ◽  
Antibody Levels ◽  
Group 1

The serum antibody response to purified pneumococcal capsular polysaccharides (PCP) was determined in four groups of infants ranging in age from 3 to 24 months. Group 1 consisted of eight infants immunized with an octavalent vaccine containing serotypes 1, 3, 6, 7, 14, 18, 19 and 23 (PCP-8). Group 1 received 25 μg of each serotype at 3–6 months of age and again at 18–24 months. The antibody response after the second immunization was compared to a group of nine patients receiving a primary immunization at 18–24 months and to a group of ten age-matched controls receiving saline placebo. There were no significant differences in mean serum antibody levels between the two groups receiving the PCP-8. A fourth group of 44 infants between 6 and 21 months of age received either PCP-7 or PCP-8 and were followed for two years, at which time simultaneous injections of both vaccines were administered. Types 2, 3, 7, and 8 were most immunogenic but levels six months after immunization were approximately the same as for unimmunized controls with the exception of serotypes 3 and 7 which persisted for about two years. The class of antibody induced either by natural infection or by immunization was preferentially IgG and it was more often induced by the former. There were no significant differences between the serotypes of pneumococci isolated from nasopharyngeal cultures regardless of which vaccine was administered. Finally, the least immunogenic serotypes include 4, 6, 14, 19, and 23 and these are the only serotypes thus far associated with otitis media after immunization. The results suggest that PCP do not induce a lasting immune tolerance at the dose administered in this study; PCP are not very immunogenic in the young infant; PCP antibody tends to rise naturally; IgG antibody is preferentially induced; nasopharyngeal colonization is not altered by PCP immunization; and an association may exist between PCP immunogenicity and subsequent onset of otitis media.

scholarly journals Detailed Multiplex Analysis of SARS-CoV-2 Specific Antibodies in COVID-19 Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Siggeir F. Brynjolfsson ◽  
Hildur Sigurgrimsdottir ◽  
Elin D. Einarsdottir ◽  
Gudrun A. Bjornsdottir ◽  
Brynja Armannsdottir ◽  
...  
Keyword(s):  
Antibody Response ◽  
Immunological Response ◽  
Receptor Binding Domain ◽  
Igg Antibody ◽  
Nucleocapsid Proteins ◽  
The Third ◽  
Antibody Isotypes ◽  
Iga Antibodies ◽  
Set Up ◽  
Antibody Levels

A detailed understanding of the antibody response against SARS-CoV-2 is of high importance, especially with the emergence of novel vaccines. A multiplex-based assay, analyzing IgG, IgM, and IgA antibodies against the receptor binding domain (RBD), spike 1 (S1), and nucleocapsid proteins of the SARS-CoV-2 virus was set up. The multiplex-based analysis was calibrated against the Elecsys® Anti-SARS-CoV-2 assay on a Roche Cobas® instrument, using positive and negative samples. The calibration of the multiplex based assay yielded a sensitivity of 100% and a specificity of 97.7%. SARS-CoV-2 specific antibody levels were analyzed by multiplex in 251 samples from 221 patients. A significant increase in all antibody types (IgM, IgG, and IgA) against RBD was observed between the first and the third weeks of disease. Additionally, the S1 IgG antibody response increased significantly between weeks 1, 2, and 3 of disease. Class switching appeared to occur earlier for IgA than for IgG. Patients requiring hospital admission and intensive care had higher levels of SARS-CoV-2 specific IgA levels than outpatients. These findings describe the initial antibody response during the first weeks of disease and demonstrate the importance of analyzing different antibody isotypes against multiple antigens and include IgA when examining the immunological response to COVID-19.

COMMITTEE ON CONTROL OF INFECTIOUS DISEASES

PEDIATRICS ◽  
1960 ◽  
Vol 26 (2) ◽  
pp. 331-332
Author(s):  
◽  
Lewis L. Coriell ◽  
John H. Dent ◽  
Horace L. Hodes ◽  
C. Henry Kempe ◽  
...  
Keyword(s):  
Young Adults ◽  
Antibody Response ◽  
Preliminary Evidence ◽  
Considerable Proportion ◽  
Inactivated Vaccine ◽  
Older Children ◽  
Poliomyelitis Vaccine ◽  
Epidemic Area ◽  
Children And Young Adults ◽  
Children Under 5

Immunization with formaldehyde-inactivated vaccine is recommended for all children and young adults. The course recommended earlier was two 1-ml intramuscular injections (1 month apart) followed by a third 1-ml injection (after an interval of approximately 7 months). This is probably adequate for older children and adults. Preliminary evidence indicates that a considerable proportion of infants have a less than optimal or relatively short-lived antibody response when immunized in this fashion. Vaccination of infants should be started at about 1½ to 2 months of age. The Committee recommends that children under 5 years of age be given a series of three 1-mi injections (1 month apart) followed by a fourth injection (up to 8 months later) and then a fifth injection (at about 4 yearsof age). In the present state of knowledge, additional injections seem advisable as indicated in Table I. A recall injection should be given before traveling abroad or before entering an epidemic area. Preparations containing inactivated poliovirus vaccine combined with diphtheria and tetanus toxoids and pertussis bacilli are now available. Such quadruple preparations should be given according to the manufacturer's directions, in general adhering to the schedule presently used for DPT (see Table I). For reasons of safety and to avoid possible loss of antigenic potency, it is considered advisable for physicians not to improvise mixtures of combined diphtheria, pertussis, and tetanus antigens and poliomyelitis vaccine. See table in the PDF file There are few contraindications to poliomyelitis vaccination. It may be performed safely at any time of the year, even when poliomyelitis is prevalent.

scholarly journals Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?

2021 ◽  
Author(s):  
Masaaki Takeuchi ◽  
Yukie Higa ◽  
Akina Esaki ◽  
Yosuke Nabeshima ◽  
Akemi Nakazono
Keyword(s):  
Antibody Production ◽  
Messenger Rna ◽  
Healthcare Workers ◽  
Adverse Reactions ◽  
Geometric Mean ◽  
Spike Protein ◽  
Igg Antibody ◽  
Blood Samples ◽  
Antibody Levels ◽  
Japanese Subjects

Adverse reactions are more common after the second injection of messenger RNA vaccines such as Pfizer/BioNTech's BNT162b2. We hypothesized that the degree and severity of reactogenicity after the second injection reflects the magnitude of antibody production against the SARS CoV-2 virus spike protein (spike IgG). Blood samples were obtained from 67 healthy Japanese healthcare workers three weeks after the first injection and two weeks after the second injection of the BNT162b2 vaccine to measure spike IgG levels. Using questionnaires, we calculated an adverse event (AE) score (0-11) for each participant. The geometric mean of spike IgG titers increased from 1,047 antibody units (AU/mL) (95% CI: 855±1282 AU/mL) after the first injection to 17,378 AU/mL (14,622±20,663 AU/mL) after the second injection. The median AE score increased from 2 to 5. Spike IgG levels after the second injection were negatively correlated with age and positively correlated with spike IgG after the first injection. AE scores after the second injection were not significantly associated with log-transformed spike IgG after the second injection, when adjusted for age, sex, and log-transformed spike IgG after the first injection. Although the sample size was relatively small, reactogenicity after the second injection may not accurately reflect antibody production.

scholarly journals The Correlation Between IgM and IgG Antibodies With Blood Profile In Patients Infected With COVID 19

2021 ◽  
Author(s):  
Zahra Alibolandi ◽  
Amirreza Ostadian ◽  
Saeed Sayyah ◽  
Hamed Haddad Kashani ◽  
Hassan Ehteram ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Antibody Response ◽  
Laboratory Data ◽  
Severe Illness ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Igg Antibody ◽  
Blood Profile ◽  
Virus Exposure ◽  
Antibody Levels

Abstract Objectives: This study aimed to determine the levels of IgM and IgG antibody response to the severe acute respiratory syndrome coronavirus (SARS-CoV)-2 in coronavirus disease 2019 (COVID-19) patients with different disease severity.Methods: IgM and IgG antibody levels were evaluated via enzyme-linked immunosorbent assay (ELISA). In total, 100 patients with confirmed SARS-CoV-2 infection were enrolled in this study and viral RNA was detected by using Real-time PCR technique. Clinical and laboratory data were collected and analyzed after hospital admission for COVID-19 and two months post-admission. Results: The level of anti-SARS-CoV-2 antibody IgG was significantly higher in the severe patients than those in moderate and mild groups, 2 months after admission. Also, level of IgG was positively associated with increased WBC, NUT and LYM counts in sever than mild or moderate groups after admission to hospital.Conclusion: Our findings suggested that patients with severe illness might experience longer virus exposure times and have a stronger antibody response against viral infection. Thus, they have longer time immunity compared with other groups.

Sign in / Sign up

Export Citation Format

Share Document